EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study

Yuxin Fan, Jiandong Yuan, Lichun Dong, Chongjing Yu, Haifeng Ding, Daosheng Xie, Runfang Guan, Ruixia Li, Wenhong Zou, Shuxian Long, Jion Chen, Yu Huang und 3 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16203 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yuxin Fan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Clinical Pharmacology, The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Yunnan Province Science and Technology Department, BrightGene Bio-Medical Technology Co., Ltd, Yunnan Province Industrial Innovation Talent Special Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Previous experiments have demonstrated that BGM0504, a GLP‐1R/GIPR dual agonist drug by molecular dynamics‐guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims to investigate its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese healthy volunteers.

Methods

A randomized, double‐blind, placebo‐controlled and dose‐escalation Phase I study was conducted as follows: a single dose (2.5 mg) and once‐weekly administration for 2 weeks to reach target doses (5, 10 and 15 mg) by titration.

Results

A total of 40 volunteers received at least one dose of BGM0504 or placebo. The PK profile of BGM0504 was investigated over a wide dose range and supported once‐weekly administration. It was observed that C max and AUC of BGM0504 were linearly proportional to the dose from 2.5–15 mg. The change in body weight (%) from baseline in BGM0504 groups was greater than that in the placebo group, with −3.24%, −6.26%, −7.09% and − 8.30% in 2.5, 5, 10 and 15 mg groups, respectively, indicating a certain dose correlation. Meanwhile, the potential roles of BGM0504 in glycaemic control were also observed. The most frequent adverse events reported were gastrointestinal (vomiting, nausea, decreased appetite, diarrhoea and abdominal distension).

Conclusion

BGM0504 was generally safe and well tolerated with favourable PK profile and potential role in weight loss was also confirmed. These findings support subsequent development of BGM0504 for type 2 diabetes mellitus (T2DM) and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsReceptors, Gastrointestinal HormoneHumansMaleAdultDouble-Blind MethodFemaleHealthy VolunteersYoung AdultDose-Response Relationship, DrugMiddle AgedBlood Glucose

Stichwörter der Autor:innen

BGM0504glucagon‐like peptide‐1glucose‐dependent insulinotropic polypeptideobesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorBlood Glucose

Autor:innen und Institutionen

  • Research Center of Clinical Pharmacology, The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
  • BrightGene Bio-Medical Technology Co., Ltd, Suzhou, China.
  • Research center for early clinical trials of Drugs (Vaccines), The Affiliated Anning First People's Hospital, Kunming University of Science and Technology, Kunming, China.
  • Clinical Development Department, Beijing Noahpharm Medical Technology Co., Ltd, Beijing, China.

ORCID-Profile: Jianchang He

Förderung

  • Yunnan Province Science and Technology Department
  • BrightGene Bio-Medical Technology Co., Ltd
  • Yunnan Province Industrial Innovation Talent Special Project
  • Yunnan Provincial Science and Technology Department

Zitieren

APA

Fan, Y., Yuan, J., Dong, L., Yu, C., Ding, H., Xie, D., Guan, R., Li, R., Zou, W., Long, S., Chen, J., Huang, Y., Yang, M., He, J., & Wen, W. (2025). The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16203

Vancouver

Fan Y, Yuan J, Dong L, Yu C, Ding H, Xie D, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16203

BibTeX
@article{Fan2025,
  author = {Fan, Yuxin and Yuan, Jiandong and Dong, Lichun and Yu, Chongjing and Ding, Haifeng and Xie, Daosheng and Guan, Runfang and Li, Ruixia and Zou, Wenhong and Long, Shuxian and Chen, Jion and Huang, Yu and Yang, Mei and He, Jianchang and Wen, Weibo},
  title = {The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16203}
}
Kostenlos starten →